Intersect ENT (XENT) Reports In-Line Q4 EPS, Slight Beat on Revenues; Offers Q1 & FY19 Revenue Guidance Below Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/15/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. HTFL
6. SNDK
7. ADYEN:NA
8. DVLT
9. ADYYF
10. WDAY

Go back to Intersect ENT (XENT) Reports In-Line Q4 EPS, Slight Beat on Revenues; Offers Q1 & FY19 Revenue Guidance Below Consensus

Intersect ENT (XENT) PT Raised to $40 at Canaccord Genuity; Sees Improving Commercial Momentum in 2019

February 26, 2019 7:32 AM EST

Canaccord Genuity analyst Kyle Rose raised the price target on Intersect ENT (NASDAQ: XENT) to $40.00 (from $36.00) while maintaining a Buy rating following results.

"While Intersect clearly lost its "beat-and-raise" luster in 2018, we believe the substantial investment in the commercial and reimbursement... More